Netherlands

Covid-19 coronavirus: Measures introduced to mitigate healthcare consequences in the Netherlands

Iradj Nazaryar

In March and April 2020, the Dutch Health and Youth Care Inspectorate (IGJ) announced various measures to mitigate the consequences of the Covid-19 coronavirus pandemic on the Dutch healthcare sector: Permission to supply medical devices that are not CE marked . Manufacturers and suppliers may temporarily supply medical devices without CE markings provided there are Read More

Netherlands – Reduction of reimbursement of medicines

Sophie van Asten

The Dutch Minister of Care announced in his letter of 27 January 2020 to the House of Representatives that the Dutch medicine reimbursement system will be modernised. The current reimbursement limits are still based on the market situation in 1998. According to the minister, nowadays there would be cheaper alternatives for many reimbursed medicines. Therefore, Read More

Dutch Minister of Care announces mandatory “base stocks” to prevent medicine shortages

Sophie van Asten

On 4 November 2019, the Dutch Minister of Care wrote a letter to the House of Representatives, proposing a solution for medicine shortages. In order to prevent shortages, additional stocks of medicines should be built up by obliging medicine manufacturers and wholesalers to build up mandatory buffers (“base stocks”) of five months’ duration, starting in Read More

Netherlands: ACM publishes evaluation of collective procurement of prescription medicines guidelines

Iradj Nazaryar

In early November 2019, the Dutch Authority for Consumers & Markets (ACM) published an evaluation of its guidelines on collective procurement of prescription medicines (2016). The guidelines provide an overview of the various options healthcare insurers and hospitals have for the collective procurement of medicine without infringing competition law, in order to create a stronger Read More

Netherlands: Debate between Dutch Minister of Care and pharmaceutical companies

Lars Braams

On 27 August 2019, the Dutch Minister of Care wrote an open letter in one of the main Dutch newspapers (De Volkskrant), addressed to pharmaceutical companies. In the letter he requested price transparency. He stated that when an explanation for a price increase is proposed by a pharmaceutical company (for example, high development costs or Read More